Rexahn Pharmaceuticals Submits Serdaxin Phase IIb Protocol To FDA For Major Depressive Disorder (MDD)
Links shared publicly online about this topic.
- 886total visits
Rexahn Pharmaceuticals Submits Serdaxin Phase IIb Protocol To FDA For Major Depressive Disorder (MDD)
View full resource at medicalnewstoday.com
Tags: Nervous System, Depression, Major Depression, Disease and Condition, Pharma, FDA, Oncology
Most Recently Shared on September 9, 2010 at 2:00 pm By:
Rexahn Pharmaceuticals Submits Serdaxin Phase IIb Protocol To FDA For Major Depressive Disorder (MDD) http://mnt.to/3JtK #regulatory
Also Shared By:
Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder
news-medical.net — “Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).” View full resource at news-medical.net
Most Recently Shared on September 7, 2010 at 1:47 pm By:
Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder: Rexahn Pharmaceutica... http://bit.ly/dqCsMS
Advertisement
MNT Depression News
@mnt_depression
Rexahn Pharmaceuticals Submits Serdaxin Phase IIb Protocol To FDA For Major Depressive Disorder (MDD) http://mnt.to/3JtK #depression
1 year ago...